ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, announced the appointment of seasoned industry veteran Charles Schweizer, PhD, as Senior Vice President of Clinical Development. Dr. Schweizer delivers more than 25 years of oncology clinical product development, regulatory, and operations experience across pharma/biotech and contract research organizations (CROs), including most recently as Therapeutic Area Head of Oncology at GSK. In his new ImmunoGenesis role, he will drive clinical development strategy and operational execution as the company prepares to initiate multiple clinical trials in 2022.
“We continue to build a powerhouse team as we enter the next phase of ImmunoGenesis’ development and prepare to enter the clinic next year,” said James Barlow, ImmunoGenesis President and CEO. “Dr. Schweizer‘s deep oncology clinical development and operations experience will power our strategy and vision for clinical development of our therapy candidates targeting immune-excluded, cold tumors where existing immunotherapies are not effective. Patients are waiting, and Dr. Schweizer is going to be critical in helping ImmunoGenesis advance its immunotherapies that have the potential to change the outcome for patients with these difficult-to-treat tumors.”
Prior to joining ImmunoGenesis, Dr. Schweizer had oversight of a global oncology portfolio of early and commercial-stage assets in his leadership role at GSK. Prior to GSK, he was Vice President, Clinical Operations, at Galera Therapeutics, a biotech company developing oncology radiotherapeutics. Previously, he spent more than 12 years at Morphotek, a biologics subsidiary of Eisai developing novel oncology monoclonal antibodies and antibody-drug conjugates, where he held various senior management positions including Vice President, Pharmaceutical Product Development. As the head of clinical product development, he was responsible for clinical and regulatory strategy, operational execution, and cross-functional alignment of the clinical pipeline at all development stages.